Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 December 2, 2024 Read More
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M February 13, 2024 Read More
Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic December 20, 2023 Read More
Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates December 20, 2023 Read More
/ News
/ News